Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP651186.RAPvuoMpzcPLMin5qnVUm5-_a4ylYWPN2bipRxS04jT3Y130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP651186.RAPvuoMpzcPLMin5qnVUm5-_a4ylYWPN2bipRxS04jT3Y130_assertion type Assertion NP651186.RAPvuoMpzcPLMin5qnVUm5-_a4ylYWPN2bipRxS04jT3Y130_head.
- NP651186.RAPvuoMpzcPLMin5qnVUm5-_a4ylYWPN2bipRxS04jT3Y130_assertion description "[When WT1 Ab was combined with CEA or CYFRA for detection of NSCLC, positive detection rates increased from 25.0 to 34.1 and 31.8%, respectively, in stage I and from 38.4 to 69.2 and 46.1%, respectively, in stage III, but not changed in stage II.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP651186.RAPvuoMpzcPLMin5qnVUm5-_a4ylYWPN2bipRxS04jT3Y130_provenance.
- NP651186.RAPvuoMpzcPLMin5qnVUm5-_a4ylYWPN2bipRxS04jT3Y130_assertion evidence source_evidence_literature NP651186.RAPvuoMpzcPLMin5qnVUm5-_a4ylYWPN2bipRxS04jT3Y130_provenance.
- NP651186.RAPvuoMpzcPLMin5qnVUm5-_a4ylYWPN2bipRxS04jT3Y130_assertion SIO_000772 19384943 NP651186.RAPvuoMpzcPLMin5qnVUm5-_a4ylYWPN2bipRxS04jT3Y130_provenance.
- NP651186.RAPvuoMpzcPLMin5qnVUm5-_a4ylYWPN2bipRxS04jT3Y130_assertion wasDerivedFrom befree-20150227 NP651186.RAPvuoMpzcPLMin5qnVUm5-_a4ylYWPN2bipRxS04jT3Y130_provenance.
- NP651186.RAPvuoMpzcPLMin5qnVUm5-_a4ylYWPN2bipRxS04jT3Y130_assertion wasGeneratedBy ECO_0000203 NP651186.RAPvuoMpzcPLMin5qnVUm5-_a4ylYWPN2bipRxS04jT3Y130_provenance.